Complix NV

Technologiepark 94

9052 Zwijnaarde

BE

Complix NV

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Upcoming events

Latest news

  • Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S.

    Friday May 17th 2024

  • 20 years of progress: flanders.bio and VIB put biotech and life sciences in spotlight

    Wednesday May 15th 2024

  • Mithra announces grant of two additional U.S. patents for NEXTSTELLIS®

    Monday May 13th 2024